AMRX – Amneal Pharmaceuticals, Inc.
Amneal Pharmaceuticals, Inc.AMRX
$7.36Name : Amneal Pharmaceuticals, Inc.
Sector : Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Mark. Cap: $3,426,072,832.00
EPSttm : -0.38
Amneal Pharmaceuticals, Inc.
$7.36
2.51%$0.18Float Short %
3.22
Margin Of Safety %
28
Put/Call OI Ratio
0.17
EPS Next Q Diff
0.08
EPS Last/This Y
1.06
EPS This/Next Y
0.12
Price
7.36
Target Price
11.67
Analyst Recom
1
Performance Q
-11.43
Relative Volume
1.23
Beta
1.21
Ticker: AMRX
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-03-20 | AMRX | 8.99 | 0.22 | 0.28 | 12492 |
| 2025-03-21 | AMRX | 8.65 | 0.22 | 0.30 | 12466 |
| 2025-03-24 | AMRX | 8.86 | 0.19 | 0.02 | 9849 |
| 2025-03-25 | AMRX | 8.52 | 0.18 | 0.00 | 10428 |
| 2025-03-26 | AMRX | 8.36 | 0.18 | 0.00 | 10640 |
| 2025-03-27 | AMRX | 8.27 | 0.18 | 0.33 | 10642 |
| 2025-03-28 | AMRX | 8.27 | 0.18 | 0.29 | 10642 |
| 2025-03-31 | AMRX | 8.38 | 0.18 | 0.02 | 10631 |
| 2025-04-01 | AMRX | 8.23 | 0.16 | 999.99 | 11608 |
| 2025-04-02 | AMRX | 8.18 | 0.16 | 0.29 | 11610 |
| 2025-04-03 | AMRX | 7.8 | 0.17 | 999.99 | 11664 |
| 2025-04-04 | AMRX | 7.39 | 0.17 | 0.57 | 11681 |
| 2025-04-07 | AMRX | 7.21 | 0.17 | 0.86 | 11677 |
| 2025-04-08 | AMRX | 6.99 | 0.17 | 30.50 | 11689 |
| 2025-04-09 | AMRX | 7.42 | 0.17 | 0.25 | 11692 |
| 2025-04-10 | AMRX | 6.95 | 0.17 | 9.00 | 11693 |
| 2025-04-11 | AMRX | 6.97 | 0.17 | 50.00 | 11685 |
| 2025-04-14 | AMRX | 7.2 | 0.17 | 1.31 | 11734 |
| 2025-04-15 | AMRX | 7.17 | 0.17 | 1.67 | 11757 |
| 2025-04-16 | AMRX | 7.17 | 0.17 | 0.04 | 11773 |
| 2025-04-17 | AMRX | 7.36 | 0.17 | 999.99 | 11814 |
| 2025-04-18 | AMRX | 7.36 | 0.17 | 999.99 | 11814 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-03-20 | AMRX | 9.01 | 19.9 | - | 0.68 |
| 2025-03-21 | AMRX | 8.65 | 19.9 | - | 0.68 |
| 2025-03-24 | AMRX | 8.89 | 12.8 | - | 0.68 |
| 2025-03-25 | AMRX | 8.53 | 12.8 | - | 0.68 |
| 2025-03-26 | AMRX | 8.36 | 12.8 | - | 0.68 |
| 2025-03-27 | AMRX | 8.26 | 5.1 | - | 0.68 |
| 2025-03-28 | AMRX | 8.28 | 5.1 | - | 0.68 |
| 2025-03-31 | AMRX | 8.38 | 5.1 | - | 0.68 |
| 2025-04-01 | AMRX | 8.23 | 5.1 | - | 0.68 |
| 2025-04-02 | AMRX | 8.17 | 5.1 | - | 0.68 |
| 2025-04-03 | AMRX | 7.80 | 5.1 | - | 0.68 |
| 2025-04-04 | AMRX | 7.39 | 5.1 | - | 0.68 |
| 2025-04-07 | AMRX | 7.20 | 5.1 | - | 0.68 |
| 2025-04-08 | AMRX | 6.99 | 5.1 | - | 0.68 |
| 2025-04-09 | AMRX | 7.43 | 5.1 | - | 0.68 |
| 2025-04-10 | AMRX | 6.95 | 5.1 | - | 0.68 |
| 2025-04-11 | AMRX | 6.98 | 5.1 | - | 0.68 |
| 2025-04-14 | AMRX | 7.21 | 5.1 | - | 0.68 |
| 2025-04-15 | AMRX | 7.17 | 5.1 | - | 0.68 |
| 2025-04-16 | AMRX | 7.17 | 5.1 | - | 0.68 |
| 2025-04-17 | AMRX | 7.36 | 5.1 | - | 0.68 |
| 2025-04-18 | AMRX | 7.36 | 5.1 | - | 0.68 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-03-20 | AMRX | -3.11 | -10.05 | 2.11 |
| 2025-03-21 | AMRX | -3.11 | -10.05 | 2.11 |
| 2025-03-24 | AMRX | -3.11 | -10.41 | 2.03 |
| 2025-03-25 | AMRX | -3.20 | -10.41 | 2.03 |
| 2025-03-26 | AMRX | -3.20 | -10.41 | 2.35 |
| 2025-03-27 | AMRX | -3.20 | -10.41 | 2.35 |
| 2025-03-28 | AMRX | -3.16 | -10.41 | 2.35 |
| 2025-03-31 | AMRX | -3.16 | -10.31 | 2.33 |
| 2025-04-01 | AMRX | -3.16 | -10.31 | 2.33 |
| 2025-04-02 | AMRX | -3.21 | -10.31 | 2.33 |
| 2025-04-03 | AMRX | -3.21 | -10.31 | 2.33 |
| 2025-04-04 | AMRX | -3.21 | -10.31 | 2.33 |
| 2025-04-07 | AMRX | -3.21 | -10.30 | 2.33 |
| 2025-04-08 | AMRX | -3.21 | -10.30 | 2.33 |
| 2025-04-09 | AMRX | -3.21 | -10.30 | 2.33 |
| 2025-04-10 | AMRX | -3.21 | -10.30 | 3.22 |
| 2025-04-11 | AMRX | -3.21 | -10.30 | 3.22 |
| 2025-04-14 | AMRX | -3.21 | -10.30 | 3.22 |
| 2025-04-15 | AMRX | -3.21 | -10.30 | 3.22 |
| 2025-04-16 | AMRX | -3.21 | -10.30 | 3.22 |
| 2025-04-17 | AMRX | -3.21 | -10.30 | 3.22 |
| 2025-04-18 | AMRX | -3.21 | -10.30 | 3.22 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
0.1
Avg. EPS Est. Current Quarter
0.15
Avg. EPS Est. Next Quarter
0.18
Insider Transactions
-3.21
Institutional Transactions
-10.3
Beta
1.21
Average Sales Estimate Current Quarter
715
Average Sales Estimate Next Quarter
764
Fair Value
9.44
Quality Score
49
Growth Score
80
Sentiment Score
64
Actual DrawDown %
22.3
Max Drawdown 5-Year %
-82.8
Target Price
11.67
P/E
Forward P/E
9.2
PEG
P/S
0.83
P/B
P/Free Cash Flow
9.83
EPS
-0.38
Average EPS Est. Cur. Y
0.68
EPS Next Y. (Est.)
0.8
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-4.18
Relative Volume
1.23
Return on Equity vs Sector %
87
Return on Equity vs Industry %
99
EPS 1 7Days Diff
EPS 1 30Days Diff
-0.07
EBIT Estimation
Amneal Pharmaceuticals, Inc.Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Employees: 8300
Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Affordable Medicines, Specialty, and AvKARE. The Affordable Medicines segment offers dosage forms and delivery systems, which include immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmics, films, transdermal patches, and topicals. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with focus on central nervous system disorders, including Parkinson's disease, and endocrine disorders. This segment provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid and ONGENTYS for the treatment of hypothyroidism; and CREXONT which is use for the treatment of Parkinson's disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers. It sells its products through wholesalers, distributors, retail pharmacies, managed care organizations, purchasing co-ops, hospitals, government agencies, institutions, and pharmaceutical companies. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.
stock quote shares AMRX – Amneal Pharmaceuticals, Inc. Stock Price stock today
news today AMRX – Amneal Pharmaceuticals, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch AMRX – Amneal Pharmaceuticals, Inc. yahoo finance google finance
stock history AMRX – Amneal Pharmaceuticals, Inc. invest stock market
stock prices AMRX premarket after hours
ticker AMRX fair value insiders trading